 Jeffrey Olsen
Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 12 | 2024 | 149 | 4.210 |
Why?
| | Chemoradiotherapy | 12 | 2024 | 225 | 2.700 |
Why?
| | Radiosurgery | 8 | 2020 | 344 | 2.380 |
Why?
| | Radiotherapy, Intensity-Modulated | 5 | 2019 | 142 | 1.850 |
Why?
| | Neoadjuvant Therapy | 11 | 2024 | 403 | 1.720 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 7 | 2020 | 130 | 1.710 |
Why?
| | Gastrointestinal Neoplasms | 6 | 2020 | 77 | 1.710 |
Why?
| | Anus Neoplasms | 3 | 2019 | 33 | 1.700 |
Why?
| | Liver Neoplasms | 8 | 2020 | 785 | 1.600 |
Why?
| | Adenocarcinoma | 11 | 2024 | 938 | 1.400 |
Why?
| | Carcinoma, Hepatocellular | 5 | 2019 | 361 | 1.260 |
Why?
| | Radiotherapy, Image-Guided | 5 | 2020 | 35 | 1.170 |
Why?
| | Esophageal Neoplasms | 4 | 2024 | 321 | 0.980 |
Why?
| | Pancreatic Neoplasms | 8 | 2022 | 935 | 0.950 |
Why?
| | Carcinoma, Squamous Cell | 4 | 2017 | 683 | 0.920 |
Why?
| | Imagination | 1 | 2024 | 18 | 0.860 |
Why?
| | Radiation Oncology | 3 | 2021 | 82 | 0.830 |
Why?
| | Technology | 1 | 2024 | 95 | 0.820 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 1682 | 0.810 |
Why?
| | Tomography, X-Ray Computed | 9 | 2020 | 2667 | 0.770 |
Why?
| | Colorectal Neoplasms | 3 | 2021 | 791 | 0.750 |
Why?
| | Prostatic Neoplasms | 4 | 2015 | 1034 | 0.740 |
Why?
| | Magnetic Resonance Imaging | 7 | 2021 | 3555 | 0.720 |
Why?
| | Radiotherapy Dosage | 8 | 2020 | 268 | 0.700 |
Why?
| | Magnetic Resonance Imaging, Interventional | 2 | 2019 | 24 | 0.670 |
Why?
| | Abdominal Neoplasms | 2 | 2016 | 39 | 0.630 |
Why?
| | Thoracic Neoplasms | 2 | 2016 | 37 | 0.630 |
Why?
| | Lymphatic Irradiation | 1 | 2019 | 10 | 0.620 |
Why?
| | Uterine Cervical Neoplasms | 2 | 2012 | 254 | 0.590 |
Why?
| | Deglutition Disorders | 1 | 2018 | 143 | 0.520 |
Why?
| | Organs at Risk | 5 | 2020 | 32 | 0.510 |
Why?
| | Intestine, Small | 2 | 2017 | 156 | 0.510 |
Why?
| | Tumor Burden | 6 | 2018 | 309 | 0.510 |
Why?
| | Aged, 80 and over | 16 | 2019 | 7585 | 0.460 |
Why?
| | Humans | 51 | 2024 | 136764 | 0.460 |
Why?
| | Fluorouracil | 5 | 2019 | 208 | 0.450 |
Why?
| | Fluorodeoxyglucose F18 | 2 | 2012 | 134 | 0.450 |
Why?
| | Catheter Ablation | 1 | 2018 | 349 | 0.450 |
Why?
| | Multimodal Imaging | 2 | 2012 | 112 | 0.450 |
Why?
| | Neoplasms | 2 | 2020 | 2644 | 0.440 |
Why?
| | Induction Chemotherapy | 4 | 2024 | 74 | 0.430 |
Why?
| | Positron-Emission Tomography | 2 | 2012 | 293 | 0.420 |
Why?
| | Prostate-Specific Antigen | 1 | 2013 | 161 | 0.400 |
Why?
| | Prone Position | 1 | 2012 | 30 | 0.390 |
Why?
| | Supine Position | 1 | 2012 | 39 | 0.380 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2021 | 1058 | 0.370 |
Why?
| | Serpins | 1 | 2010 | 31 | 0.340 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2012 | 267 | 0.330 |
Why?
| | Middle Aged | 22 | 2024 | 33228 | 0.330 |
Why?
| | Aged | 19 | 2024 | 23794 | 0.320 |
Why?
| | Movement | 2 | 2011 | 272 | 0.320 |
Why?
| | Biomarkers, Tumor | 3 | 2018 | 1272 | 0.310 |
Why?
| | Radiopharmaceuticals | 3 | 2018 | 177 | 0.310 |
Why?
| | Diagnostic Imaging | 2 | 2024 | 328 | 0.300 |
Why?
| | Early Detection of Cancer | 1 | 2013 | 417 | 0.300 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2013 | 1076 | 0.300 |
Why?
| | Imaging, Three-Dimensional | 1 | 2012 | 576 | 0.290 |
Why?
| | Mitomycin | 2 | 2019 | 34 | 0.290 |
Why?
| | Lung Neoplasms | 5 | 2013 | 2489 | 0.290 |
Why?
| | Antigens, Neoplasm | 1 | 2010 | 319 | 0.280 |
Why?
| | Tomography, Spiral Computed | 1 | 2007 | 32 | 0.280 |
Why?
| | Neoplasm Staging | 5 | 2023 | 1371 | 0.280 |
Why?
| | Yttrium Radioisotopes | 2 | 2018 | 57 | 0.270 |
Why?
| | Respiration | 1 | 2007 | 199 | 0.260 |
Why?
| | Antineoplastic Agents | 2 | 2019 | 2122 | 0.260 |
Why?
| | Disease-Free Survival | 4 | 2017 | 685 | 0.240 |
Why?
| | Radiotherapy | 2 | 2017 | 201 | 0.240 |
Why?
| | Algorithms | 3 | 2015 | 1689 | 0.240 |
Why?
| | Practice Guidelines as Topic | 3 | 2024 | 1571 | 0.230 |
Why?
| | Embolization, Therapeutic | 2 | 2018 | 229 | 0.230 |
Why?
| | Treatment Outcome | 9 | 2023 | 10744 | 0.220 |
Why?
| | Combined Modality Therapy | 3 | 2024 | 1231 | 0.220 |
Why?
| | Preoperative Care | 2 | 2017 | 356 | 0.220 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 351 | 0.220 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2007 | 752 | 0.200 |
Why?
| | Pancreas | 2 | 2023 | 329 | 0.200 |
Why?
| | Organoplatinum Compounds | 3 | 2017 | 45 | 0.200 |
Why?
| | Leucovorin | 3 | 2017 | 81 | 0.200 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1261 | 0.190 |
Why?
| | Medical Oncology | 1 | 2024 | 289 | 0.180 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 888 | 0.180 |
Why?
| | Biliary Tract Neoplasms | 1 | 2020 | 30 | 0.160 |
Why?
| | Adult | 13 | 2024 | 37630 | 0.160 |
Why?
| | Male | 18 | 2024 | 67309 | 0.160 |
Why?
| | Follow-Up Studies | 5 | 2024 | 5106 | 0.160 |
Why?
| | Female | 17 | 2024 | 72787 | 0.160 |
Why?
| | Workflow | 2 | 2020 | 165 | 0.160 |
Why?
| | Duodenum | 2 | 2016 | 77 | 0.150 |
Why?
| | Stomach | 2 | 2016 | 110 | 0.150 |
Why?
| | Technetium Tc 99m Aggregated Albumin | 1 | 2018 | 6 | 0.150 |
Why?
| | Serum Albumin, Human | 1 | 2018 | 6 | 0.150 |
Why?
| | Bilirubin | 1 | 2018 | 97 | 0.140 |
Why?
| | Rectum | 3 | 2020 | 185 | 0.140 |
Why?
| | Observer Variation | 2 | 2015 | 341 | 0.140 |
Why?
| | Chemoembolization, Therapeutic | 1 | 2018 | 91 | 0.140 |
Why?
| | Matched-Pair Analysis | 1 | 2017 | 39 | 0.140 |
Why?
| | Colon | 2 | 2017 | 282 | 0.140 |
Why?
| | Precision Medicine | 1 | 2021 | 426 | 0.130 |
Why?
| | Age Factors | 2 | 2017 | 3284 | 0.130 |
Why?
| | Microspheres | 1 | 2016 | 137 | 0.130 |
Why?
| | Pelvis | 1 | 2017 | 102 | 0.120 |
Why?
| | Pelvic Neoplasms | 1 | 2015 | 26 | 0.120 |
Why?
| | Camptothecin | 1 | 2016 | 115 | 0.120 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2015 | 25 | 0.120 |
Why?
| | ROC Curve | 1 | 2017 | 545 | 0.120 |
Why?
| | Liposarcoma | 1 | 2015 | 27 | 0.120 |
Why?
| | Retrospective Studies | 9 | 2024 | 15504 | 0.110 |
Why?
| | Lung | 1 | 2007 | 4052 | 0.110 |
Why?
| | Regression Analysis | 1 | 2017 | 1022 | 0.110 |
Why?
| | Radiation Injuries | 1 | 2015 | 145 | 0.110 |
Why?
| | Acute Disease | 1 | 2017 | 1004 | 0.110 |
Why?
| | Prostate | 2 | 2015 | 175 | 0.110 |
Why?
| | Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 19 | 0.100 |
Why?
| | Gastrointestinal Tract | 1 | 2015 | 195 | 0.100 |
Why?
| | Feasibility Studies | 1 | 2017 | 951 | 0.100 |
Why?
| | Thoracic Wall | 1 | 2012 | 18 | 0.090 |
Why?
| | Motion | 1 | 2012 | 98 | 0.090 |
Why?
| | Patient Positioning | 1 | 2012 | 67 | 0.090 |
Why?
| | Karnofsky Performance Status | 1 | 2011 | 38 | 0.090 |
Why?
| | Image Enhancement | 1 | 2012 | 190 | 0.090 |
Why?
| | Pneumonectomy | 1 | 2013 | 152 | 0.090 |
Why?
| | Patient Care Team | 1 | 2016 | 626 | 0.090 |
Why?
| | Computer Systems | 1 | 2011 | 45 | 0.090 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2011 | 141 | 0.090 |
Why?
| | Rotation | 1 | 2011 | 114 | 0.090 |
Why?
| | Neoplasm Invasiveness | 1 | 2012 | 507 | 0.090 |
Why?
| | Survival Rate | 3 | 2024 | 1962 | 0.080 |
Why?
| | Carcinoembryonic Antigen | 2 | 2022 | 39 | 0.080 |
Why?
| | Software | 2 | 2016 | 665 | 0.080 |
Why?
| | Head and Neck Neoplasms | 1 | 2015 | 604 | 0.080 |
Why?
| | Survival Analysis | 1 | 2012 | 1321 | 0.080 |
Why?
| | Capecitabine | 2 | 2020 | 45 | 0.070 |
Why?
| | Analysis of Variance | 1 | 2011 | 1316 | 0.070 |
Why?
| | Quality Improvement | 1 | 2016 | 1163 | 0.070 |
Why?
| | Inhalation | 1 | 2007 | 29 | 0.070 |
Why?
| | Exhalation | 1 | 2007 | 39 | 0.070 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1935 | 0.070 |
Why?
| | Artifacts | 1 | 2007 | 129 | 0.070 |
Why?
| | Prognosis | 2 | 2018 | 4013 | 0.070 |
Why?
| | Deoxycytidine | 2 | 2019 | 179 | 0.060 |
Why?
| | Pain | 1 | 2012 | 754 | 0.060 |
Why?
| | Bile Duct Neoplasms | 1 | 2007 | 123 | 0.060 |
Why?
| | Cohort Studies | 2 | 2016 | 5701 | 0.060 |
Why?
| | Esophagogastric Junction | 1 | 2024 | 51 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2012 | 3264 | 0.060 |
Why?
| | Quality of Life | 1 | 2016 | 2878 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2018 | 1507 | 0.050 |
Why?
| | Risk Assessment | 1 | 2012 | 3432 | 0.050 |
Why?
| | Trypanosoma brucei rhodesiense | 1 | 2002 | 1 | 0.050 |
Why?
| | Trypanocidal Agents | 1 | 2002 | 2 | 0.050 |
Why?
| | Diphosphonates | 1 | 2002 | 66 | 0.050 |
Why?
| | Albumins | 1 | 2022 | 113 | 0.050 |
Why?
| | Paclitaxel | 1 | 2022 | 227 | 0.040 |
Why?
| | Watchful Waiting | 1 | 2021 | 80 | 0.040 |
Why?
| | Brachytherapy | 1 | 2020 | 121 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2021 | 610 | 0.040 |
Why?
| | Quality Assurance, Health Care | 1 | 2020 | 322 | 0.040 |
Why?
| | Aspartate Aminotransferases | 1 | 2018 | 90 | 0.040 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 528 | 0.030 |
Why?
| | Time Factors | 2 | 2018 | 6806 | 0.030 |
Why?
| | Duodenal Ulcer | 1 | 2016 | 13 | 0.030 |
Why?
| | Erlotinib Hydrochloride | 1 | 2016 | 72 | 0.030 |
Why?
| | Lymphocytes | 1 | 2018 | 393 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1044 | 0.030 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2015 | 17 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2015 | 31 | 0.030 |
Why?
| | Perioperative Period | 1 | 2015 | 56 | 0.030 |
Why?
| | Neutropenia | 1 | 2016 | 146 | 0.030 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2015 | 105 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2018 | 504 | 0.030 |
Why?
| | Penis | 1 | 2015 | 36 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1462 | 0.030 |
Why?
| | Anemia | 1 | 2016 | 170 | 0.030 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2015 | 387 | 0.030 |
Why?
| | Thrombocytopenia | 1 | 2016 | 198 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 320 | 0.030 |
Why?
| | Gastrointestinal Diseases | 1 | 2016 | 209 | 0.030 |
Why?
| | Pancreatectomy | 1 | 2016 | 252 | 0.030 |
Why?
| | Sarcoma | 1 | 2015 | 188 | 0.020 |
Why?
| | Urinary Bladder | 1 | 2015 | 183 | 0.020 |
Why?
| | Neutrophils | 1 | 2018 | 1236 | 0.020 |
Why?
| | Liver | 1 | 2021 | 1940 | 0.020 |
Why?
| | Consensus | 1 | 2015 | 678 | 0.020 |
Why?
| | Treatment Failure | 1 | 2013 | 354 | 0.020 |
Why?
| | Patient Satisfaction | 1 | 2016 | 656 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2013 | 657 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2022 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4143 | 0.020 |
Why?
| | Biopsy | 1 | 2013 | 1124 | 0.020 |
Why?
| | Computer Simulation | 1 | 2013 | 973 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2750 | 0.020 |
Why?
| | Prospective Studies | 1 | 2019 | 7572 | 0.020 |
Why?
| | Logistic Models | 1 | 2012 | 2067 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2016 | 2639 | 0.010 |
Why?
| | Risk Factors | 1 | 2018 | 10326 | 0.010 |
Why?
| | Lethal Dose 50 | 1 | 2002 | 15 | 0.010 |
Why?
| | Quantitative Structure-Activity Relationship | 1 | 2002 | 19 | 0.010 |
Why?
| | Quantum Theory | 1 | 2002 | 78 | 0.010 |
Why?
| | United States | 1 | 2018 | 14691 | 0.010 |
Why?
| | Crystallography, X-Ray | 1 | 2002 | 476 | 0.010 |
Why?
| | Tumor Cells, Cultured | 1 | 2002 | 953 | 0.010 |
Why?
| | Models, Molecular | 1 | 2002 | 1570 | 0.010 |
Why?
| | Animals | 1 | 2002 | 36823 | 0.000 |
Why?
|
|
Olsen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|